Elligo secures $16m to scale clinical trials tech

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/	BrianAJackson)
(Image: Getty/ BrianAJackson)
Elligo Health Research has closed a $16m Series B funding round, which will help scale the company’s business and support development of new technology solutions for clinical trials.

The funding round was led by Hatteras Venture Partners and Noro-Moseley Partners with participation from FS Healthcare LLC and Excelerate Health Ventures.

Elligo did not provide any comment on the Series A round, though some of the initial investors, including Shumway Capital, did also participate in the second round, the company said.

The Series B funds will be used to expand the scale of the business “after a very successful 2016 and 2017,”​ said John Potthoff, Elligo CEO.

“In addition, we will be supporting the implementation of technology solutions with support of Saama,” ​he told us.

Elligo earlier this month​ announced a partnership with Saama Technologies through which the companies will build new technology platforms to help sponsors achieve their objectives faster, Potthoff told us at the time.

The platform will leverage Saama’s Life Science Analytics Cloud to support patient population identification based on clinical trial eligibility requirements.

Related news

Show more

Related products

show more

QPS: Global Custom-Built Research Services

QPS: Global Custom-Built Research Services

QPS | 16-Dec-2019 | Product Brochure

Performing complex studies in special populations with remarkable agility. Clinical research just got better with QPS’ Custom-Built Research Services....

Validating The Simoa Technology

Validating The Simoa Technology

Frontage Laboratories | 01-Oct-2019 | Technical / White Paper

Frontage is the first and only laboratory to validate Quanterix’ Simoa HD1 Analyzer for performing immunoassays. Most of the advanced instruments used...

Related suppliers

Follow us

Products

View more

Webinars